NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent Patents.
CONCLUSION: The vigorous effort to discover and develop agents to specifically inhibit NLRP3 inflammasome activation, may pave the way to therapeutic intervention targeting inflammasome-regulated pathways that are involved in the pathogenesis of various forms of cancer.
PMID: 29076433 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
More News: Academia | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Fibrosarcoma | Gastric (Stomach) Cancer | Gastroenterology | Immunotherapy